Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience
Table 1
Baseline biochemical parameters and BMD in the whole group of patients under teriparatide, and separately, in those with (AR-prior) and without (AR-naïve) previous antiresorptive treatment.
Basal characteristics
Whole group (n = 264)
AR-naïve (n = 56)
AR-prior (n = 208)
Age (years)
68.7 ± 10.2
66.2 ± 11.6
69.4 ± 9.7#
Body mass index (kg/m2)
24.7 ± 4.3
25.8 ± 5.4
24.4 ± 4.1
Serum calcium (mg/dL) (n. v: 8.5–10.5)
9.5 ± 0.4
9.5 ± 0.4
9.5 ± 0.5
Urinary calcium (mg/24 h)
149.8 ± 66.1
159.8 ± 74.5
147.1 ± 63.6
Calcium/creatinine (mg/mg)
0.2 ± 0.1
0.2 ± 0.1
0.2 ± 0.1
Serum phosphate (mg/dL) (n. v: 2.5–4.5)
3.8 ± 0.5
3.6 ± 0.5
3.8 ± 0.5#
Serum magnesium (mg/dL) (n. v: 1.9–2.3)
2.1 ± 0.2
2.1 ± 0.2
2.0 ± 0.2
Serum uric acid (mg/dL) (n. v: 2.4–6)
4.4 ± 1.0
4.5 ± 1.0
4.3 ± 1.0
25 (OH) vitamin D (ng/mL)
33.6 ± 12.7
30.6 ± 10.4
34.4 ± 13.0
PTH (pg/mL) (n. v: 10–65)
45.0 ± 18.8
43.5 ± 15.7
44.9 ± 19.8
Total alkaline phosphatase (IU/L) (n. v: <270)
145.3 ± 67.3
142.7 ± 67.6
143.7 ± 67.7
Bone alkaline phosphatase (μg/L) (n.v: 5.2–24.4)
16.9 ± 10.7
24.2 ± 16.5
21.2 ± 14.5
Osteocalcin (ng/mL) (n. v: 11–43)
18.4 ± 10.8
22.8 ± 12.6
17.4 ± 10.1#
Urine deoxypyridinoline (nM/mM Cr) (n. v: 3–7.4)
7.4 ± 2.9
7.6 ± 1.4
7.5 ± 3.1
s-CTX (ng/ml) (n. v: 40–590)
356.80 ± 191.5
438.1 ± 187.0
334.4 ± 187.4#
Lumbar spine BMD (g/cm2; T-score)
0.807 ± 0.125; −3.3 ± 0.9
0.804 ± 0.141
0.807 ± 0.121
Femoral neck BMD (g/cm2; T-score)
0.682 ± 0.106; −2.5 ± 1.0
0.693 ± 0.123
0.679 ± 0.101
Total hip BMD (g/cm2; T-score)
0.711 ± 0.109; −2.5 ± 1.0
0.714 ± 0.135
0.710 ± 0.099
Mean ± SD. #Indicates significant differences vs. AR-naïve.
